H.C. Wainwright Reiterates Buy on Omeros After AstraZeneca’s Ultomiris Phase 3 Miss
AstraZeneca’s Ultomiris Phase 3 miss in adult HSCT-TMA is a clear positive for Omeros’ Yartemlea, removing a key rival.
Already have an account? Sign in.